Microbial-based Cancer Therapy -Bugs as Drugs (R21 Clinical Trial Not Allowed)

Funding Opportunity PAR-19-194 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to stimulate the development of novel microbial-based cancer therapies, especially for conditions where conventional cancer therapies are inadequate, such as poorly vascularized, hypoxic, solid tumors, dormant or slowly dividing cells resistant to current interventions, and brain tumors. Utilizing bacteria, archaebacteria, bacteriophages and other non-virus microorganisms, this initiative will support research projects designed to study the underlying mechanisms of the complex interactions between microorganisms, tumor, and immune system. The FOA also aims to support research into the use of microorganisms as delivery vehicles for cancer treatme...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2XvtLvJ